Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      TSO3 Reports Fourth Quarter and Full Year 2018 Results


      News provided by

      TSO3 Inc.

      Mar 27, 2019, 20:14 ET

      Share this article

      Share this article


      QUEBEC CITY and MYRTLE BEACH, SC, March 27, 2019 /PRNewswire/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the fourth quarter and year ended December 31, 2018.

      Business Highlights

      In the fourth quarter of 2018, TSO3 received purchase orders for a record 21 units of its industry-leading STERIZONE® VP4 Sterilizer and shipped nine sterilizers to end users. 

      The Company continues to aggressively uncover new opportunities and now has over 450 sterilizers in its qualified sales pipeline.  The Company expects to achieve purchase orders and commitment indications for more than 10 sterilizers in the first quarter of 2019 and currently has 75 STERIZONE® VP4 Sterilizers installed at end customer locations. 

      "In 2018, TSO3 pivoted from a third-party distribution model to that of a direct sales strategy.  This action was taken to increase the pace of deployment of our propriety STERIZONE® VP4 Sterilizer," stated R.M. (Ric) Rumble, president and CEO of TSO3. "Since taking these actions, we are experiencing end customer adoption at rates in excess of past performance, which gives us an early indication that we are on the right path."

      2018 Fourth Quarter Financial Summary

      • Revenues equaled $1.1 million, as compared to $0.8 million in the third quarter of 2018 and $5.8 million in the fourth quarter of 2017. TSO3 revenues in the fourth quarter of 2018 reflect sales of sterilizers and related accessories, service and $0.4 million of consumables directly to end customers. The Company shipped nine sterilizers to hospitals in the fourth quarter of 2018 as opposed to four sterilizers to hospitals in the third quarter of 2018 and 50 sterilizers to its former distributor in the fourth quarter of 2017.
      • Gross profit was $0.04 million on an IFRS basis ($0.6 million, or 52% of revenues, on a non-IFRS basis after excluding a non-recurring write-down of $0.5 million of raw material inventories), as compared to $1.2 million, or 150% of revenues, in the third quarter of 2018 and $2.3 million, or 40% of revenues, in the fourth quarter of 2017.
      • Research and Development (R&D) expenses amounted to $1.1 million on an IFRS basis ($0.7 million on a non-IFRS basis after excluding a non-recurring write-down of $0.4 million on sterilizers developed internally that will not be commercialized in the upcoming year), as compared to $1.3 million in the third quarter of 2018 and $1.8 million in the fourth quarter of 2017.
      • Sales, General and Administrative (SG&A) expenses were $2.7 million, as compared to $2.6 million in the third quarter of 2018 and $2.0 million in the fourth quarter of 2017.
      • Financial income was $1.1 million, as compared to $0.6 million in the third quarter of 2018 and an immaterial amount in the fourth quarter of 2017. The Company recorded $0.8 million of accrued interest expense in the fourth quarter of 2018 related to a $20.0 million debt financing it obtained in August 2018 and a non-cash gain of $1.8 million on the revaluation of the embedded derivative within the Convertible Note associated with this financing.
      • The Company's net loss was $(2.7) million, or $(0.03) per share, as compared to $(2.1) million, or $(0.02) per share, in the third quarter of 2018 and to $(1.4) million, or $(0.02) per share in the fourth quarter of 2017.
      • The Company had $13.0 million in cash, cash equivalents and investments and $18.0 million of debt as of December 31, 2018, as compared to $16.1 million in cash, cash equivalents and investments and $19.1 million of debt at the end of the third quarter of 2018.
      • Cash used by the operating activities was $3.0 million, $0.9 million of which was used in working capital items.

      2018 Full Year Financial Summary

      • Revenues equaled $2.5 million in 2018, which includes shipments of 13 sterilizers to medical facilities end customers and associated accessories, consumables and service, as compared to $19.7 million in 2017 which included shipments of 170 sterilizers to our former distributor along with accessories, consumables, service and license fee revenue recognition.
      • Gross profit was $1.0 million, or 39% of revenues in 2018, as compared to $7.7 million, or 39% of revenues, in 2017.
      • R&D expenses were $5.5 million in 2018, as compared to $6.2 million in 2017. The Company reduced its research and development expenditures as it focused more of its expenditures on selling and marketing activities.
      • SG&A expenses were $10.3 million in 2018, as compared to $8.7 million in 2017 as the Company grew its sales and marketing team members and activities while decreasing general and administrative expenditures.
      • Financial income was $1.7 million, as compared to a financial expense of $0.1 million in 2017. The Company recorded $1.2 million of accrued interest expense related to a $20.0 million debt financing it obtained on August 1, 2018 and a non-cash gain of $2.9 million on the revaluation of the embedded derivative within the Convertible Note associated with this financing.
      • The Company net loss and comprehensive loss totaled $(13.2) million or $(0.14) per share, as compared to $(7.5) million or $(0.08) per share of net loss and comprehensive loss in 2017.

      Supplemental Non-IFRS Financial Measures

      In addition to IFRS financial measures, management uses non-IFRS financial measures to assess the Company's operational performance. It is likely that the non-IFRS financial measures used by the Company will not be comparable to similar measures reported by other issuers or those used by financial analysts as their measures may have different definitions. The measures used by the Company are intended to provide additional information and should not be considered in isolation or as a substitute for IFRS financial performance measures.

      Generally, a non-IFRS financial measure is a numerical measure of an entity's historical or future financial performance, financial position or cash flows that is neither calculated nor recognized under IFRS. Management believes that such non-IFRS financial measures are important as they provide users of the financial statements with a better understanding of the results of the Company's recurring operations and their related trends, while increasing transparency and clarity into its operating results. Management also believes these measures can be useful in assessing the Company's capacity to discharge its financial obligations.

      Management is assessing its operational performance using supplemental non-IFRS measures which removes significant unusual items that do not reflect the recurring and ongoing operational results and trends.

      Additional Fourth Quarter and Full Year 2018 Financial information



      2018

      2017

      $000's

      Q4

      Q3

      Q2

      Q1

      Q4

      Q3

      Q2

      Q1

      Net (loss)

      (2,676)

      (2,104)

      (3,952)

      (4,512)

      (1,449)

      (1,771)

      (2,254)

      (1,980)

      Financial (income) expenses

      (1,055)

      (599)

      (12)

      (14)

      74

      48

      49

      (39)

      Amortization and depreciation

      235

      270

      292

      315

      246

      331

      221

      168

      Write-down of tangible and intangible assets

      1,026

      -

      -

      -

      -

      -

      -

      -

      Share-based compensation expense

      369

      688

      627

      371

      301

      632

      592

      609

      Income taxes

      7

      11

      7

      -

      (59)

      33

      29

      27

      Adjusted Ebitda

      (2,094)

      (1,734)

      (3,038)

      (3,840)

      (887)

      (727)

      (1,363)

      (1,215)

      Adjusted EBITDA, is adjusted Earnings before Interest, Taxes, Depreciation, and Amortization (Adjusted EBITDA). Adjusted EBITDA adjusts net income for (1) significant realized and unrealized foreign exchange gains or losses, (2) financial expenses (income), (3) amortization and depreciation expenses (4) share-based compensation expense, (5) write-downs of certain tangible and intangible assets, (6) one-time write-off of inventory, (7) income taxes, and (8) other significant unusual items.

      Summary of Results

      Year ended December 31 (Unaudited, IFRS Basis, in thousands of US dollars, except per share amounts)



      2018

      2017


      $

      $

      Revenues

      2,532

      19,726

      Cost of sales

      1,534

      12,068

      Gross profit

      998

      7,658

      Expenses



      Research and development

      5,547

      6,222

      Selling, general and administrative

      10,348

      8,728

      Financial (income) expenses

      (1,678)

      132

      Total Expenses

      14,217

      15,082

      Net loss before income taxes

      (13,219)

      (7,424)

      Income taxes

      25

      30

      Net loss and comprehensive loss

      (13,244)

      (7,454)

      Weighted average number of outstanding shares (in thousands)

      93,108

      92,508

      Basic and diluted net loss per share

      (0.14)

      (0.08)

      Basic and diluted net comprehensive loss per share

      (0.14)

      (0.08)

      Fourth Quarter Analysis

      (Unaudited, IFRS Basis, in thousands of US dollars, except per share amounts)


      Three-month period ended December 31, 2018, compared to the three-month period ended December 31, 2017:



      Fourth Quarter

      2018

      Fourth Quarter

      2017


      $

      $

      Revenues

      1,122

      5,780

      Cost of sales

      1,083

      3,455

      Gross profit

      39

      2,325




      Expenses



      Research and development

      1,095

      1,766

      Selling, general and administrative

      2,667

      1,993

      Financial (income) expenses

      (1,054)

      74

      Total Expenses

      2,708

      3,833

      Net loss before income taxes

      (2,669)

      (1,508)

      Income taxes

      7

      (59)

      Net loss and comprehensive loss

      (2,676)

      (1,449)

      Weighted average number of outstanding shares (in thousands)

      93,108

      92,508

      Basic and diluted net loss per share

      (0.03)

      (0.02)

      Basic and diluted net comprehensive loss per share

      (0.03)

      (0.02)

      Consolidated Statements of Financial Position

      As of December 31, 2018, and 2017 (Unaudited, IFRS Basis, in thousands of US dollars)



      2018

      2017


      $

      $

      Current Assets



      Cash and Cash Equivalents

      12,961

      8,044

      Investments

      -

      6,764

      Accounts Receivable

      1,591

      651

      Inventories

      3,534

      2,040

      Current Tax Assets

      16

      -

      Prepaid Expenses

      261

      150


      18,363

      17,649

      Non-current Assets



      Property, Plant and Equipment

      2,039

      3,184

      Intangible Assets

      1,781

      1,886


      3,820

      5,070


      22,183

      22,719

      Current Liabilities



      Accounts Payable and Accrued Liabilities

      1,858

      2,430

      Warranty Provision

      273

      1,263

      Current Tax Liabilities

      -

      68

      Deferred Revenues

      103

      6


      2,234

      3,767

      Non-current Liabilities



      Deferred Tax Liabilities

      51

      17

      Debt

      16,711

      -

      Embedded Derivative

      1,319

      -

      Deferred Revenues

      -

      6,044


      20,315

      9,828

      Equity



      Share Capital

      111,470

      111,215

      Reserve – Share-based Compensation

      8,540

      6,574

      Deficit

      (116,430)

      (103,186)

      Accumulated Other Comprehensive Loss

      (1,712)

      (1,712)


      1,868

      12,891


      22,183

      22,719

      Consolidated Statements of Cash Flows



      As of December 31, 2018 and 2017 (Unaudited, IFRS Basis, in thousands of US dollars)







      2018

      2017


      $

      $

      Cash flows from operating activities



      Net loss

      (13,244)

      (7,454)

      Adjustments for:



      Depreciation and amortization

      1,112

      966

      Loss on write-down of property, plant and equipment

      450

      46

      Loss on write-down of intangibles assets

      98

      -

      Loss on write-down of inventories

      544

      -

      Income tax

      (84)

      (92)

      Deferred income tax liabilities

      34

      68

      Share-based Compensation

      2,055

      2,134

      Reversal of warranty provision

      (973)

      -

      Capitalized interest on long term debt

      1,210

      -

      Gain on re-measurement at fair-value on embedded derivative

      (2,898)

      -

      Investment income

      (111)

      (131)


      (11,807)

      (4,463)

      Changes in non-cash operating working capital items

      (9,730)

      1,148

      Interest received

      149

      185

      Cash flows used by operating activities

      (21,388)

      (3,130)

      Cash flows from investing activities



      Acquisition of investments

      -

      (6,349)

      Disposal of investments

      6,726

      16,091

      Acquisition of property, plant and equipment

      (107)

      (1,569)

      Acquisition of intangible assets

      (198)

      (239)

      Proceed from disposal of property, plant and equipment

      -

      2

      Cash flows used in investing activities

      6,421

      7,936

      Cash flows from financing activities



      Issuance of debt net of financing fees

      20,000

      -

      Financing fee

      (282)

      -

      Options exercised

      166

      540

      Cash flows generated by financing activities

      19,884

      540

      Increase in cash and cash equivalents

      4,917

      5,346

      Cash and cash equivalents at the beginning

      8,044

      2,698

      Cash and cash equivalents at the end

      12,961

      8,044

      Consolidated Statements of Cash Flows

      (Unaudited, IFRS Basis, in thousands of US dollars)


      Three-month period ended December 31, 2018, compared to the three-month period ended December 31, 2017:






      Q4-2018

      Q4-2017


      $

      $

      Cash flows from operating activities



      Net loss

      (2,676)

      (1,449)

      Adjustments for:



      Depreciation and amortization

      235

      251

      Loss on write-down of property, plant and equipment   

      384

      6

      Loss on write-down of intangible assets

      98

      -

      Loss on write-down of inventories

      544

      -

      Current and Deferred income tax liabilities

      (50)

      (113)

      Capitalized interest on long term debt

      765

      -

      Gain on re-measurement at fair value on embedded derivative

      (1,795)

      -

      Share-based compensation

      369

      301

      Investment income

      (42)

      8


      (2,168)

      (996)

      Changes in non-cash operating working capital items

      (894)

      265

      Interest received

      43

      57

      Cash flows used in operating activities

      (3,019)

      (674)

      Cash flows from investing activities



      Acquisition of investments

      -

      (3,440)

      Disposal of investments

      -

      5,077

      Acquisition of property, plant and equipment

      (10)

      (513)

      Acquisition of intangible assets

      (96)

      (50)

      Cash flows used in investing activities

      (106)

      1,074

      Cash flows from financing activities



      Financing fee

      4

      -

      Cash flows generated by financing activities

      4

      -

      Increase (decrease) in cash and cash equivalents

      (3,121)

      400

      Cash and cash equivalents at the beginning

      16,082

      7,644

      Cash and cash equivalents at the end

      12,961

      8,044

      Conference call

      TSO3 President and CEO R.M. (Ric) Rumble and CFO Glen Kayll, will host the conference call, followed by a question and answer period.

      Date:

      Thursday, March 28, 2019

      Time:

      8:30 a.m. Eastern Daylight Time 

      Toll-free dial-in number:

      1-888-231-8191

      International dial-in number:

      1-514-807-9895 (Montreal); 1-647-427-7450 (Toronto)

      Conference ID:

      3932989

      Analysts and institutional investors are invited to participate on the call. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Danielle Ste-Marie, Ste-Marie Strategy & Communications Inc., Tel: 1-514-465-6701  

      Other interested parties may listen to the live webcast of the conference call at https://event.on24.com/wcc/r/1950265/F70721F46E344D3AB217AD37866C4EE2 which will be available for replay in the Investors section of the Company's website at www.tso3.com.  

      Fourth Quarter and Fiscal 2018 Results Disclosure

      The 2018 Annual Report is available on TSO3's website at www.tso3.com and full 2018 disclosure will shortly be available on SEDAR (www.sedar.com).

      About the STERIZONE® VP4 Sterilizer

      The STERIZONE VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture-sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error-free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

      The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize long, multi-channel flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length - an industry first for any medical device sterilization process.

      The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb.  The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).

      More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at www.tso3.com.

      About TSO3

      Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

      For more information about TSO3, visit the Company's website at www.tso3.com.

      The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the limited history of sales or distribution of the Company, the evolution in customer demand for the Company's products and services, the plans for sales and marketing including the fact that the Company's customers may not commit to any purchases, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3's actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2018, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.

      SOURCE TSO3 Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.